Santen Pharmaceutical Co (4536) Price & Analysis

Compare

0 Followers

4536 Stock Chart & Stats

Day’s Range― - ―

52-Week Range¥1,310.50 - ¥1,878.50

Previous CloseN/A

Volume1.29M

Average Volume (3M)1.17M

Market Cap

¥503.57B

Enterprise Value¥510.34B

Total Cash (Recent Filing)¥77.85B

Total Debt (Recent Filing)¥0.00

Price to Earnings (P/E)18.8

Beta0.44

Next Earnings

May 13, 2025

EPS Estimate

18.99

Last Dividend Ex-Date

Mar 28, 2025

Dividend Yield2.44%

Share Statistics

EPS (TTM)78.31

Shares Outstanding342,055,540

10 Day Avg. Volume775,490

30 Day Avg. Volume1,167,496

Financial Highlights & Ratios

PEG Ratio6.83

Price to Book (P/B)N/A

Price to Sales (P/S)0.00

Price to Cash Flow (P/CF)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

¥2,199.51

Price Target Upside49.22% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

---

Santen Pharmaceutical Co News

PremiumCompany Announcements

Santen Pharmaceutical Co. Revises Year-End Dividend Forecast

3M ago

PremiumCompany Announcements

Santen Pharmaceutical to Cancel 5 Million Treasury Shares

3M ago

PremiumCompany Announcements

Santen Pharmaceutical Reports Financial Results and Strategic Initiatives

3M ago

PremiumPre-Earnings

SNPHF Upcoming Earnings Report: What to Expect?

3M ago

PremiumCompany Announcements

Santen Pharmaceutical Completes Strategic Share Buyback

5M ago

PremiumCompany Announcements

Santen Pharmaceutical’s Strategic Share Buyback Update

5M ago

PremiumThe Fly

Clearside Biomedical’s partner signed new collaboration agreement with Santen

6M ago

CLSD

PremiumCompany Announcements

Santen Pharmaceutical Co. Reports Mixed Financial Results

6M ago

See All JP:4536 News

---

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

―

Insiders

7.63%

Mutual Funds

― Other Institutional Investors

86.03% Public Companies and

Individual Investors

Detailed Ownership Overview >

4536 FAQ

What was Santen Pharmaceutical Co ’s price range in the past 12 months?

Santen Pharmaceutical Co lowest stock price was ¥1310.50 and its highest was ¥1878.50 in the past 12 months.

What is Santen Pharmaceutical Co ’s market cap?

Santen Pharmaceutical Co ’s market cap is ¥503.57B.

When is Santen Pharmaceutical Co ’s upcoming earnings report date?

Santen Pharmaceutical Co ’s upcoming earnings report date is May 13, 2025 which is in 9 days.

How were Santen Pharmaceutical Co ’s earnings last quarter?

Santen Pharmaceutical Co released its earnings results on Feb 06, 2025. The company reported ¥25.33 earnings per share for the quarter, missing the consensus estimate of ¥26.114 by -¥0.784.

Is Santen Pharmaceutical Co overvalued?

According to Wall Street analysts Santen Pharmaceutical Co ’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Santen Pharmaceutical Co pay dividends?

Santen Pharmaceutical Co pays a Annually dividend of ¥17 which represents an annual dividend yield of 2.44%. See more information on Santen Pharmaceutical Co dividends here

What is Santen Pharmaceutical Co ’s EPS estimate?

Santen Pharmaceutical Co ’s EPS estimate is 18.99.

How many shares outstanding does Santen Pharmaceutical Co have?

Santen Pharmaceutical Co has 342,055,540 shares outstanding.

What happened to Santen Pharmaceutical Co ’s price movement after its last earnings report?

Santen Pharmaceutical Co reported an EPS of ¥25.33 in its last earnings report, missing expectations of ¥26.114. Following the earnings report the stock price went down -3.536%.

Which hedge fund is a major shareholder of Santen Pharmaceutical Co ?

Currently, no hedge funds are holding shares in JP:4536

---

Company Description

Santen Pharmaceutical Co

Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.

---

4536 Stock 12 Month Forecast

Average Price Target

¥2,199.51

▲(49.22% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1333":"¥1,333","2200":"¥2,200","1549.75":"¥1,549.8","1766.5":"¥1,766.5","1983.25":"¥1,983.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2199.5070320037,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥2.20K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2199.5070320037,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥2.20K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2199.5070320037,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥2.20K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1333,1549.75,1766.5,1983.25,2200],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2021","6":"Apr<br/>2021","9":"Aug<br/>2021","12":"Feb<br/>2025","25":"Feb<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1545.987,1596.2577716925923,1646.5285433851845,1696.799315077777,1747.0700867703692,1797.3408584629615,1847.6116301555537,1897.882401848146,1948.1531735407384,1998.4239452333306,2048.694716925923,2098.9654886185153,2149.2362603111073,{"y":2199.5070320037,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1545.987,1596.2577716925923,1646.5285433851845,1696.799315077777,1747.0700867703692,1797.3408584629615,1847.6116301555537,1897.882401848146,1948.1531735407384,1998.4239452333306,2048.694716925923,2098.9654886185153,2149.2362603111073,{"y":2199.5070320037,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1545.987,1596.2577716925923,1646.5285433851845,1696.799315077777,1747.0700867703692,1797.3408584629615,1847.6116301555537,1897.882401848146,1948.1531735407384,1998.4239452333306,2048.694716925923,2098.9654886185153,2149.2362603111073,{"y":2199.5070320037,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1536.54,"date":1601510400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1536.54,"date":1604188800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1536.54,"date":1606780800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1536.54,"date":1609459200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1567.073,"date":1612137600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1334.482,"date":1614556800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1390.103,"date":1617235200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1390.103,"date":1617235200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1370.167,"date":1625097600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1370.167,"date":1627776000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1619.609,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1731.071,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1545.987,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >